Newswise — Orlando, Florida (April 23, 2018) – Orlando Health UF Health Cancer Center is the first to dose a patient in a study for an experimental drug to treat metastatic breast cancer in post-menopausal women.

The SHERBOC study is a clinical trial of MM-121 (seribantumab), a drug developed by Merrimack Pharmaceuticals, Inc. to target cancer cells resistant to common anti-tumor therapies.

The international, multi-site study will investigate the drug in post-menopausal patients with heregulin-positive, hormone receptor-positive, HER2-negative breast cancer – a common type of the disease that comprises 75 percent of all breast cancer diagnoses in the United States. MM-121 is designed for patients who have not had success fighting their disease after one or two lines of prior systemic therapies for advanced breast cancer.    

“We’re excited to once again be on the leading edge of research and have one of our patients be the first anywhere to participate in this study,” says Regan Rostorfer, M.D., breast cancer specialist and principal investigator for the SHERBOC study at Orlando Health UF Health Cancer Center. “The findings of this study could have a major impact on countless breast cancer patients and potentially open doors to a new treatment option, offering hope and a greater chance for survival.”   

The SHERBOC study is the newest clinical trial being offered at Orlando Health UF Health Cancer Center. To learn more about other active clinical trials, visit: 

About Orlando Health UF Health Cancer Center

Orlando Health UF Health Cancer Center is a collaboration of top cancer doctors and leading cancer researchers from Orlando Health and the University of Florida Health advancing new treatment options into clinical practice. One of Florida’s largest comprehensive cancer care providers with multiple locations across Central Florida, Orlando Health UF Health Cancer Center offers specialized cancer treatment through a multidisciplinary approach that encompasses a team of medical specialists who work closely together to determine the best possible treatment for each patient. Signature programs include genetics, drug development, and biomarkers for personalized medicine. For more information, visit



Register for reporter access to contact details